Jupiter, Florida – October 16, 2026 -- Myosin Therapeutics will present its first-in-class cancer candidate MT-125 at BioFuture 2026 in New York City on October 27–28, seeking investors and pharmaceutical partners to fund an extension into two additional treatment-resistant cancers.

New York City – – September 29, 2026 -- Demy-Colton has released the agenda for BioFuture 2026, a two-day conference set for October 27–28 at Cure, 345 Park Avenue South, drawing more than 100 speakers and over 50 presenting companies from biopharma, investment, technology and policy sectors.